4.7 Review

Radiation-Induced Sarcoma of the Breast: A Systematic Review

期刊

ONCOLOGIST
卷 17, 期 3, 页码 405-418

出版社

WILEY
DOI: 10.1634/theoncologist.2011-0282

关键词

Radiation-induced; Radiotherapy; Breast cancer; Second primary malignancy; Sarcoma; Angiosarcoma

类别

资金

  1. Supergen
  2. Threshold
  3. Biovex
  4. Bristol Myers Squibb
  5. Progen
  6. Ziopharm
  7. Varian Medical Systems
  8. Sysmex Corp
  9. Department of Surgery of the University of Arizona

向作者/读者索取更多资源

Introduction. Radiation-induced sarcoma (RIS) is a rare, aggressive malignancy. Breast cancer survivors treated with radiotherapy constitute a large fraction of RIS patients. To evaluate evidenced-based practices for RIS treatment, we performed a systematic review of the published English-language literature. Methods. We performed a systematic keyword search of PubMed for original research articles pertaining to RIS of the breast. We classified and evaluated the articles based on hierarchal levels of scientific evidence. Results. We identified 124 original articles available for analysis, which included 1,831 patients. No randomized controlled trials involving RIS patients were found. We present the best available evidence for the etiology, comparative biology to primary sarcoma, prognostic factors, and treatment options for RIS of the breast. Conclusion. Although the evidence to guide clinical practice is limited to single institutional cohort studies, registry studies, case-control studies, and case reports, we applied the available evidence to address clinically relevant questions related to best practice in patient management. Surgery with widely negative margins remains the primary treatment of RIS. Unfortunately, the role of adjuvant and neoadjuvant chemotherapy remains uncertain. This systematic review highlights the need for additional well-designed studies to inform the management of RIS. The Oncologist 2012; 17: 405-418

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据